1363382-91-5

Usage

Uses

Used in Pharmaceutical Research:
1-Boc-3-(hydroxyMethyl)-3-Methylazetidine is used as a building block in the synthesis of complex molecules for the development of potential therapeutic agents. Its versatility as an intermediate allows for the creation of drug candidates with various biological activities.
Used in Medicinal Chemistry:
1-Boc-3-(hydroxyMethyl)-3-Methylazetidine is used as a versatile intermediate in medicinal chemistry for the design and synthesis of biologically active compounds. Its unique structure and functional groups contribute to the development of novel compounds with potential therapeutic applications.
Used in Organic Synthesis:
1-Boc-3-(hydroxyMethyl)-3-Methylazetidine is used as a key component in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications across various industries.
Used in Drug Development:
1-Boc-3-(hydroxyMethyl)-3-Methylazetidine is used as a precursor in the preparation of drug candidates, facilitating the discovery of new therapeutic agents with potential applications in treating various diseases and conditions.

Upstream product

• 610791-05-4 azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 887591-62-0 1-[(tert-butoxy)carbonyl]-3-methylazetidine-3-carboxylic acid 
• 898228-37-0 3-methyl-azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 

Downstream Products

• 1458653-12-7 3-hydroxymethyl-3-methyl-azetidine hydrochloride 

Relevant academic research and scientific papers

TRPV4 RECEPTOR LIGANDS

Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.